

RWE Q&A

How will our RWE study help cancer patients with pain?

Our RWE study will be on patients already being treated with pain medicines, eg Opioids, which do not work or are inappropriate for many thousands of patients. Our unique blend of cannabis-based medicine will treat these patients to alleviate this pain and continuing suffering in this RWE study over a four-month period.

How will our RWE study lead to share-holder value?

The patients recruited into the RWE study will have an individual agreement with each hospital to ensure that the NHS pays for these patients at the end of the 4-month study. These results, together with a publication will add value to the shareholders.

Why is cancer related pain an unmet clinical need?

When patients are being treated with a medication that is not satisfactory and there is nothing else available then there is an unmet clinical need for a new type of treatment. In the UK there are over 600 thousand patients that are not being treated adequately for their pain associated with cancer.

How credible is our RWE Study and how it will lead to cancer patients being recruited quickly?

The NCRI is the UK National Cancer Research Institute and they have endorsed our RWE Study which means that all the main Cancer hospitals, including the world leading, Royal Marsden and Christie's in Manchester, will be taking part in recruiting the patients across the UK over the 4 months duration of the study.

What happens at the end of the study?

All patients will be paid for by the NHS at the end of the study, whilst new patients will be recruited for a second study in an area where it is needed.

Is this the right time to do such a study and why has this type of RWE study not been done before?

Regulation for research with Cannabis based products was only allowed when the changes were announced in November 2018 and only recently in the last year have the UK regulatory body, the MHRA, and the evidence-based body, NICE agreed that more research is needed along with a government endorsement and patient demand.

How can our medicine be prescribed without a pharmaceutical licence which takes years to get at a cost?

Our Cannabis based medicine will be prescribed with a "specials licence" which is the case for many products and may well lead to continuing research jointly with a

pharmaceutical company. The first cannabis based medicinal product has already been prescribed and paid for by the NHS recently.

The statements made on this page are the views of management and have not been reviewed or approved by Crowd for Angels as part of the investment pitch. All investment decisions should be made on the basis of information provided in the company's investment pitch only.